Fenofibrate has been shown to inhibit SARS-CoV-2 replication in vitro. Results from a randomized clinical trial show that treating patients with COVID-19 with fenofibrate has no significant effect on clinically relevant outcomes.
- Julio A. Chirinos
- Patricio Lopez-Jaramillo
- Pedro Antonio Segura-Saldaña